Biotic acts of antibiotics

Frontiers in Microbiology

Volumn 4, Issue AUG, 2013, Pages

  Aminov, Rustam I ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Cancer; Cardiovascular; Inflammation; Macrolides; Neuroprotection; Respiratory; Tetracyclines; lactam

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; MINOCYCLINE; TACROLIMUS; TELITHROMYCIN; TETRACYCLINE;

ABDOMINAL AORTA ANEURYSM; ADULT RESPIRATORY DISTRESS SYNDROME; AMYOTROPHIC LATERAL SCLEROSIS; ANTIMICROBIAL ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BACTERIAL MENINGITIS; BIOLOGICAL ACTIVITY; BRAIN ISCHEMIA; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PERIODONTITIS; CHRONIC RESPIRATORY TRACT DISEASE; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DEPRESSION; DISEASE EXACERBATION; GONORRHEA; GRAFT REJECTION; HOSPITALIZATION; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; LYME DISEASE; METASTASIS; MYOCARDITIS; NEUROLOGIC DISEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; TYPHOID FEVER;

EUKARYOTA; MAMMALIA;

EID: 84884237650     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2013.00241     Document Type: Review

References (213)

1. Abdul-Hussien, H., Hanemaaijer, R., Verheijen, J. H., van Bockel, J. H., Geelkerken, R. H., and Lindeman, J. H. (2009). Doxycycline aneurysm: improved proteolytic balance through reduced neutrophil content. J. Vasc. Surg. 49, 741-749. doi: 10.1016/j.jvs.2008.09.055
2. Abraham, R. T. (1998). Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine 10, 330-336. doi: 10.1016/S0952-7915(98)80172-6
3. Adler, C. J., Dobney, K., Weyrich, L. S., Kaidonis, J., Walker, A. W., Haak, W., et al. (2013). Sequencing ancient calcified dental plaque microbiota with dietary shifts of the Neolithic and Industrial revolutions. Nat. Genet. 45, 450-455. doi: 10.1038/ng.2536
4. Alajaji, M., Bowers, M. S., Knackstedt, L., and Damaj, M. I. (2013). Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal reinstatement of preference in mice. Psychopharmacology (Berl.) 228, 419-426. doi: 10.1007/s00213-013-3047-32013
5. Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. Jr., Criner, G. J., et al. (2011). Azithromycin for prevention of exacerbations Med. 365, 689-698. doi: 10.1056/NEJMoa1104623
6. Altenburg, J., de Graaff, C. S., Stienstra, Y., Sloos, J. H., van Haren, E. H., Koppers, R. J., et al. (2013). Effect of azithromycin maintenance exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309, 1251
7. Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P. R., Patel, R. N., et al. (1996). A novel mechanism of action of tetracyclines: synthases. Proc. Natl. Acad. Sci. U.S.A. 93, 14014-14019. doi: 10.1073/pnas.93.24.14014
8. Aminov, R. I. (2009). The role of antibiotics and antibiotic resistance in nature. Environ. Microbiol. 11, 2970-2988. doi: 10.1111/j.
9. Aminov, R. I. (2013). Evolution in action: dissemination of tet(X) into pathogenic microbiota. Front. Microbiol. 4:192. doi: 10.3389/
10. Amsden, G. W. (2001). Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18(Suppl. 1), S11 00410-1
11. Armitage, G. C. (2013). Learned and unlearned concepts in periodontal diagnostics: a 50-year perspective. Periodontol. 2000
12. Barak, S., Liu, F., Hamida, S. B., Yowell, Q. V., Neasta, J., Kharazia, V., et al. (2013). Disruption of alcohol-related memories by mTORC1 Nat. Neurosci. 16, 1111-1117. doi: 10.1038/nn.3439
13. Bartold, P. M., and Van Dyke, T. E. (2013). Periodontitis: a host-mediated disruption of microbial homeostasis. Unlearning learned 203-217. doi: 10.1111/j.1600-0757.2012.00450.x
14. Bartynski, W. S., Tan, H. P., Boardman, J. F., Shapiro, R., and Marsh, J. W. (2008). Posterior reversible encephalopathy syndrome AJNR Am. J. Neuroradiol. 29, 924-930. doi: 10.3174/ajnr.A0960
15. Baumgart, D. C., MacDonald, J. K., and Feagan, B. G. (2008). Tacrolimus (FK506) for induction of remission in refractory ulcerative Syst. Rev. 16, CD007216. doi: 10.1002/14651858.CD007216
16. Baumgart, D. C., Pintoffl, J. P., Sturm, A., Wiedenmann, B., and Dignass, A. U. (2006). Tacrolimus is safe and effective in patients steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 101, 1048-1056. doi: 10.1111/j.1572
17. Berry, J. D., Shefner, J. M., Conwit, R., Schoenfeld, D., Keroack, M., Felsenstein, D., et al. (2013). Design and initial results of a multi ceftriaxone in amyotrophic lateral sclerosis. PLoS ONE 8:e61177. doi: 10.1371/journal.pone.0061177
18. Bertrand, X., and Dowzicky, M. J. (2012). Antimicrobial susceptibility among gram-negative isolates collected from intensive care the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and 124-137. doi: 10.1016/j.clinthera.2011.11.023
19. Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., et al. (2009). Minocycline promotes dendritic spine maturation performance in the fragile X mouse model. J. Med. Genet. 46, 94-102. doi: 10.1136/jmg.2008.061796
20. Blasi, F., Bonardi, D., Aliberti, S., Tarsia, P., Confalonieri, M., Amir, O., et al. (2010). Long-term azithromycin use in patients with disease and tracheostomy. Pulm. Pharmacol. Ther. 23, 200-207. doi: 10.1016/j.pupt.2009.12.002
21. Bosnar, M., Kragol, G., Koštrun, S., Vujasinoviæ, I., Bošnjak, B., Bencetiæ Mihaljeviæ, V., et al. (2012). N'-substitutednovel anti-inflammatory macrolides without antimicrobial activity. J. Med. Chem. 55, 6111-6123. doi: 10.1021/jm300356u
22. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., et al. (1994). A mammalian protein targeted by G1 complex. Nature 369, 756-758. doi: 10.1038/369756a0
23. Burkholder, P. R., and Ruetzler, K. (1969). Antimicrobial activity of some marine sponges. Nature 222, 983-984. doi: 10.1038/222983a0
24. Burton, C. L., Chhabra, S. R., Swift, S., Baldwin, T. J., Withers, H., Hill, S. J., et al. (2002). The growth response of Escherichia coli catecholamine drugs requires a functional enterobactin biosynthesis and uptake system. Infect. Immun. 70, 5913-5923. doi:
25. Carrell, R. W., and Lomas, D. A. (1997). Conformational disease. Lancet 350, 134-138. doi: 10.1016/S0140-6736(97)02073
26. Casha, S., Zygun, D., McGowan, M. D., Bains, I., Yong, V. W., and Hurlbert, R. J. (2012). Results of a phase II placeboacute spinal cord injury. Brain 135, 1224-1236. doi: 10.1093/brain/aws072
27. Castro, M. M., Tanus-Santos, J. E., and Gerlach, R. F. (2011). Matrix metalloproteinases: targets for doxycycline to prevent the vascular Pharmacol. Res. 64, 567-572. doi: 10.1016/j.phrs.2011.04.002
28. Caton, J., and Ryan, M. E. (2011). Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline 63, 114-120. doi: 10.1016/j.phrs.2010.12.003
29. Chang, K. M., Ryan, M. E., Golub, L. M., Ramamurthy, N. S., and McNamara, T. F. (1996). Local and systemic factors degrading enzyme activities in rat gingiva: effect of micocycline therapy. Res. Commun. Mol. Pathol. Pharmacol. 91, 303
30. Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., et al. (2000). Minocycline inhibits caspase-1 and caspase transgenic mouse model of Huntington disease. Nat. Med. 6:797-801. doi: 10.1038/80538
31. Chen, Z., He, Y., and Wang, Z. J. (2012). The beta-lactam antibiotic, ceftriaxone, inhibits the development of opioid-induced hyperalgesia 509, 69-71. doi: 10.1016/j.neulet.2011.12.029
32. Choi, Y., Kim, H. S., Shin, K. Y., Kim, E. M., Kim, M., Kim, H. S., et al. (2007). Minocycline attenuates neuronal cell death and improves Alzheimer's disease models. Neuropsychopharmacology 32, 2393-2404. doi: 10.1038/sj.npp.1301377
33. Chu, K., Lee, S. T., Sinn, D. I., Ko, S. Y., Kim, E. H., Kim, J. M., et al. (2007). Pharmacological induction of ischemic tolerance by glutamate upregulation. Stroke 38, 177-182. doi: 10.1161/01.STR.0000252091.36912.65
34. Clarke, M. B., Hughes, D. T., Zhu, C., Boedeker, E. C., and Sperandio, V. (2006). The QseC sensor kinase: a bacterial adrenergic receptor. U.S.A. 103, 10420-10425. doi: 10.1073/pnas.0604343103
35. Cruzado, J. M. (2008). Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant. Rev. (Orlando). 10.1016/j.trre.2007.09.003
36. Danbolt, N. C. (2001). Glutamate uptake. Prog. Neurobiol. 65, 1-105. doi: 10.1016/S0301-0082(00)00067-8
37. Dalvi, P. S., Singh, A., Trivedi, H. R., Ghanchi, F. D., Parmar, D. M., and Mistry, S. D. (2011). Effect of doxycycline in patients of moderate obstructive pulmonary disease with stable symptoms. Ann. Thorac. Med. 6, 221-226. doi: 10.4103/1817-1737.84777
38. Davies, J., Spiegelman, G. B., and Yim, G. (2006). The world of subinhibitory antibiotic concentrations. Curr. Opin. Microbiol. 10.1016/j.mib.2006.08.006
39. Dean, O. M., Data-Franco, J., Giorlando, F., and Berk, M. (2012). Minocycline: therapeutic potential in psychiatry. CNS Drugs 000000000-00000
40. Del Rosso, J. Q. (2007). Recently approved systemic therapies for acne vulgaris and rosacea. Cutis 80, 113-120.
41. Dey, B. P., Reamer, R. P., Thaker, N. H., and Thaler, A. M. (2005). Calf antibiotic and sulfonamide test (CAST) for screening antibiotic calf carcasses. J. AOAC Int. 88, 440-446.
42. Dezube, B. J., Krown, S. E., Lee, J. Y., Bauer, K. S., and Aboulafia, D. M. (2006). Randomized phase II trial of matrix metalloproteinase related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol. 24, 1389-1394. doi: 10.1200/JCO.2005.04.2614
43. Dodel, R., Spottke, A., Gerhard, A., Reuss, A., Reinecker, S., Schimke, N., et al. (2010). Minocycline 1-year therapy in multiple symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov. Disord. 25, 97-107. doi: 10.1002/mds.22732
44. Drucker, A. M., and Rosen, C. F. (2011). Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 000000000-00000
45. Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., et al. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 14669-14674. doi: 10.1073/pnas.251341998
46. Elewa, H. F., Hilali, H., Hess, D. C., Machado, L. S., and Fagan, S. C. (2006). Minocycline for short-term neuroprotection. 10.1592/phco.26.4.515
47. Encinar, J. A., Mallo, G. V., Mizyrycki, C., Giono, L., Gonzalez-Ros, J. M., Rico, M., et al. (2001). Human p8 is a HMGenhanced by phosphorylation. J. Biol. Chem. 276, 2742-2751. doi: 10.1074/jbc.M008594200
48. Federici, T. J. (2011). The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol. Res. 10.1016/j.phrs.2011.06.013
49. Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., et al. (2011). Increased intestinal permeability alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE 6:e28032. doi: 10.1371/journal.
50. Gabler, W. L., and Creamer, H. R. (1991). Suppression of human neutrophil functions by tetracyclines. J. Periodontal Res. 0765.1991.tb01626.x
51. Gao, F., Li, M., Liu, Y., Gao, C., Wen, S., and Tang, L. (2012). Intestinal dysbacteriosis induces changes of T lymphocyte subpopulations and orients the immune response towards humoral immunity. Gut Pathog. 4, 19. doi: 10.1186/1757-4749-4-19
52. Garrido-Mesa, N., Zarzuelo, A., and Gálvez, J. (2013). Minocycline: far beyond an antibiotic. Br. J. Pharmacol. 169, 337
53. Glatz, M., and Hofbauer, G. F. (2012). Phototoxic and photoallergic cutaneous drug reactions. Chem. Immunol. Allergy
54. Gluud, C., Als-Nielsen, B., Damgaard, M., Fischer Hansen, J., Hansen, S., Helø, O. H., et al. (2008). Clarithromycin for 2 weeks for year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. 10.1159/000128994
55. Golub, L. M. (2011). Introduction and background. Pharmacol. Res. 63, 99-101. doi: 10.1016/j.phrs.2010.10.003
56. Golub, L. M., Lee, H. M., Lehrer, G., Nemiroff, A., McNamara, T. F., Kaplan, R., et al. (1983). Minocycline reduces gingival collagenolytic Preliminary observations and a proposed new mechanism of action. J. Periodontal Res. 18, 516-526. doi: 10.1111/j.1600
57. Golub, L. M., McNamara, T. F., D'Angelo, G., Greenwald, R. A., and Ramamurthy, N. S. (1987). A non-antibacterial chemically mammalian collagenase activity. J. Dent. Res. 66, 1310-1314. doi: 10.1177/00220345870660080401
58. Golub, L. M., Ramamurthy, N. S., McNamara, T. F., Greenwald, R. A., and Rifkin, B. R. (1991). Tetracyclines inhibit connective tissue implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 2, 297-321.
59. Good, J. T. Jr., Rollins, D. R., and Martin, R. J. (2012). Macrolides in the treatment of asthma. Curr. Opin. Pulm. Med. 10.1097/MCP.0b013e32834daff8
60. Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., et al. (2007). Efficacy of minocycline in patients sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045-1053. doi: 10.1016/S1474-4422(07)70270-3
61. Goruppi, S., Patten, R. D., Force, T., and Kyriakis, J. M. (2007). Helix-loop-helix protein p8, a transcriptional regulator required for cardiac fibroblast matrix metalloprotease induction. Mol. Cell. Biol. 27, 993-1006. doi: 10.1128/MCB.00996-06
62. Greenwald, R. A. (2011). The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol. Res. 10.1016/j.phrs.2011.06.010
63. Grenier, D., Plamondon, P., Sorsa, T., Lee, H. M., McNamara, T., Ramamurthy, N. S., et al. (2002). Inhibition of proteolytic, serpinolytic, activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. 10.1902/jop.2002.73.1.79
64. Gu, Y., Lee, H. M., Sorsa, T., Salminen, A., Ryan, M. E., Slepian, M. J., et al. (2011). Non-antibacterial tetracyclines modulate mediators atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. Pharmacol. Res.
65. Gu, Y., Walker, C., Ryan, M. E., Payne, J. B., and Golub, L. M. (2012). Non-antibacterial tetracycline formulations: clinical applications Oral Microbiol. 4. doi: 10.3402/jom.v4i0.19227
66. Gunduz, O., Oltulu, C., and Ulugol, A. (2011). Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the mice. Pharmacol. Biochem. Behav. 99, 100-103. doi: 10.1016/j.pbb.2011.04.012
67. Gurk-Turner, C., Manitpisitkul, W., and Cooper, M. (2012). A comprehensive review of everolimus clinical reports: a new Transplantation 94, 659-668. doi: 10.1097/TP.0b013e31825b411c
68. Hammerstrom, A. E., Howell, J., Gulbis, A., Rondon, G., Champlin, R. E., and Popat, U. (2013). Tacrolimus-associated posterior reversible syndrome in hematopoietic allogeneic stem cell transplantation. Am. J. Hematol. 88, 301-305. doi: 10.1002/ajh.23402
69. Hanemaaijer, R., Sorsa, T., Konttinen, Y. T., Ding, Y., Sutinen, M., Visser, H., et al. (1997). Matrix metalloproteinase-8 is expressed fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J. Biol. Chem. 272, 31504
70. Harry, G. J. (2013). Microglia during development and aging. Pharmacol. Ther. doi: 10.1016/j.pharmthera.2013.04.013 [Epub ahead
71. Henneman, A., and Thornby, K. A. (2012). Risk of hypotension with concomitant use of calcium-channel blockers and Pharm. 69, 1038-1043. doi: 10.2146/ajhp110486
72. Hishikari, K., Watanabe, R., Ogawa, M., Suzuki, J., Masumura, M., Shimizu, T., et al. (2010). Early treatment with clarithromycin attenuates myocarditis via inhibition of matrix metalloproteinase activity. Heart 96, 523-527. doi: 10.1136/hrt.2009.188094
73. Ho, S., Clipstone, N., Timmermann, L., Northrop, J., Graef, I., Fiorentino, D., et al. (1996). The mechanism of action of cyclosporin Immunopathol. 80:S40-S45. doi: 10.1006/clin.1996.0140
74. Hodnett, P., Coyle, J., O'Regan, K., Maher, M. M., and Fanning, N. (2009). PRES (posterior reversible encephalopathy syndrome), therapy. Emerg. Radiol. 16, 493-496. doi: 10.1007/s10140-008-0782-6
75. Hoffmeister, A., Ropolo, A., Vasseur, S., Mallo, G. V., Bodeker, H., Ritz-Laser, B., et al. (2002). The HMG-I/Y-related protein p8 binds activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the Chem. 277, 22314-22319. doi: 10.1074/jbc.M201657200
76. Holloway, R. A., and Donnelly, L. E. (2013). Immunopathogenesis of chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 10.1097/MCP.0b013e32835cfff5
77. Huttner, B., Jones, M., Rubin, M. A., Neuhauser, M. M., Gundlapalli, A., and Samore, M. (2012). Drugs of last resort? The use of polymyxins Veterans Affairs medical centers, 2005-2010. PLoS ONE 7:e36649. doi: 10.1371/journal.pone.0036649
78. Ištuk, Z. M., Cikoš, A., Gembarovski, D., Lazarevski, G., Diloviæ, I., Matkoviæ-Èalogoviæ, D., et al. (2011). Novel 9a,11 substituted 2-imino-1,3-oxazolidines condensed to an azalide aglycone. Bioorg. Med. Chem. 19, 556-566. doi: 10.1016/j.bmc.2010.10.061
79. Jin, W. J., Feng, S. W., Feng, Z., Lu, S. M., Qi, T., and Qian, Y. N. (2013). Minocycline improves postoperative cognitive impairment astrocytic activation. Neuroreport doi: 10.1097/WNR.0b013e3283629195 [Epub ahead of print].
80. Joks, R., and Durkin, H. G. (2011). Effect of tetracyclines on IgE allergic responses and asthma. Recent Pat. Inflamm. Allergy Drug 10.2174/187221311797264919
81. Jonat, C., Chung, F. Z., and Baragi, V. M. (1996). Transcriptional downregulation of stromelysin by tetracycline. J. Cell. Biochem. 1097-4644(19960301)60:3
82. Kalivas, P. W., Lalumiere, R. T., Knackstedt, L., and Shen, H. (2009). Glutamate transmission in addiction. Neuropharmacology 10.1016/j.neuropharm.2008.07.011
83. Karavolos, M. H., Spencer, H., Bulmer, D. M., Thompson, A., Winzer, K., Williams, P., et al. (2008). Adrenaline modulates the global Salmonella revealing a role in the antimicrobial peptide and oxidative stress resistance responses. BMC Genomics 9:458. doi: 10.1186/
84. Karavolos, M. H., Winzer, K., Williams, P., and Khan, C. M. (2013). Pathogen espionage: multiple bacterial adrenergic sensors eavesdrop systems. Mol. Microbiol. 87, 455-465. doi: 10.1111/mmi.12110
85. Kato, T. A., Watabe, M., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., et al. (2012). Minocycline modulates human social decision microglia on personality-oriented social behaviours. PLoS ONE 7:e40461. doi: 10.1371/journal.pone.0040461
86. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., et al. (1987). FK-506, a novel immunosuppressant isolated Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40, 1249-1255. doi: 10.7164/antibiotics.
87. Knackstedt, L. A., Melendez, R. I., and Kalivas, P. W. (2010). Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine 67, 81-84. doi: 10.1016/j.biopsych.2009.07.018
88. Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Higaki, M., Mikura, S., et al. (2013). A novel macrolide solithromycin exerts superior NF-ΚB inhibition. J. Pharmacol. Exp. Ther. 345, 76-84. doi: 10.1124/jpet.112.200733
89. Kong, F., Chen, S., Cheng, Y., Ma, L., Lu, H., Zhang, H., et al. (2013). Minocycline attenuates cognitive impairment induced by isoflurane PLoS ONE 8:e61385. doi: 10.1371/journal.pone.0061385
90. Kraus, R. L., Pasieczny, R., Lariosa-Willingham, K., Turner, M. S., Jiang, A., and Trauger, J. W. (2005). Antioxidant properties of minocycline: oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 94, 819-827. doi: 10.1111/j.1471-4159.2005.03219.x
91. Kudoh, S., Uetake, T., Hagiwara, K., Hirayama, M., Hus, L. H., Kimura, H., et al. (1987). Clinical effects of low-dose long panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25, 632-642.
92. Lai, A. Y., and Todd, K. G. (2006). Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. 10.1002/glia.20335
93. Lai, P. C., Huang, Y. T., Wu, C. C., Lai, C. J., Wang, P. J., and Chiu, T. H. (2011). Ceftriaxone attenuates hypoxic-ischemic brain injury Sci. 18, 69. doi: 10.1186/1423-0127-18-69
94. Lamming, D. W., Ye, L., Sabatini, D. M., and Baur, J. A. (2013). Rapalogs and mTOR inhibitors as anti-aging therapeutics. 10.1172/JCI64099
95. Laport, M. S., Santos, O. C., and Muricy, G. (2009). Marine sponges: potential sources of new antimicrobial drugs. Curr. Pharm. Biotechnol. 10.2174/138920109787048625
96. Ledeboer, A., Sloane, E. M., Milligan, E. D., Frank, M. G., Mahony, J. H., Maier, S. F., et al. (2005). Minocycline attenuates mechanical proinflammatory cytokine expression in rat models of pain facilitation. Pain 115, 71-83. doi: 10.1016/j.pain.2005.02.009
97. Leiva, M., Ruiz-Bravo, A., and Jiménez-Valera, M. (2008a). Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide inflammation. Chest 134, 20-29. doi: 10.1378/chest.07-3056
98. Leiva, M., Ruiz-Bravo, A., Moreno, E., and Jiménez-Valera, M. (2008b). Telithromycin inhibits the production of proinflammatory NF-kappaB in in vitro-stimulated murine cells. FEMS Immunol. Med. Microbiol. 53, 343-350. doi: 10.1111/j.1574-695X.2008.00424.
99. Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., et al. (2010). A double-blind, randomized study of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71, 138-149. doi: 10.4088/JCP.08m04666yel
100. Lewerenz, J., Albrecht, P., Tien, M. L., Henke, N., Karumbayaram, S., Kornblum, H. I., et al. (2009). Induction of Nrf2 and xCT are neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111, 332-343. doi: 10.1111/j.1471-4159.2009.06347.x
101. Li, S. Y., Xia, L. X., Zhao, Y. L., Yang, L., Chen, Y. L., Wang, J. T., et al. (2013). Minocycline mitigates isoflurane-induced cognitive Res. 1496, 84-93. doi: 10.1016/j.brainres.2012.12.025
102. Linares, J. F., Gustafsson, I., Baquero, F., and Martinez, J. L. (2006). Antibiotics as intermicrobial signalling agents instead of weapons. 103, 19484-19489. doi: 10.1073/pnas.0608949103
103. Lokeshwar, B. L. (1999). MMP inhibition in prostate cancer. Ann. N. Y. Acad Sci. 878, 271-289. doi: 10.1111/j.1749-6632.1999.tb07690.
104. Lokeshwar, B. L. (2011). Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. 10.1016/j.phrs.2010.11.003
105. Lutz, L., Pereira, D. C., Paiva, R. M., Zavascki, A. P., and Barth, A. L. (2012). Macrolides decrease the minimal inhibitory concentration against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol. 12:196. doi: 10.1186/1471-2180
106. Mallo, G. V., Fiedler, F., Calvo, E. L., Ortiz, E. M., Vasseur, S., Keim, V., et al. (1997). Cloning and expression of the rat p8 cDNA, a during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. 10.1074/jbc.272.51.32360
107. Malmo, C., Vilasi, S., Iannuzzi, C., Tacchi, S., Cametti, C., Irace, G., et al. (2006). Tetracycline inhibitsW7FW14F apomyoglobin fibril amyloid protein in a pre-fibrillar, highly cytotoxic state. FASEB J. 20, 346-347.
108. Mannino, D. M., and Buist, A. S. (2007). Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370, 765 61380-4
109. Maragakis, N. J., and Rothstein, J. D. (2001). Glutamate transporters in neurologic disease. Arch. Neurol. 58, 365-370. doi: 10.1001/
110. Marchand, F., Tsantoulas, C., Singh, D., Grist, J., Clark, A. K., Bradbury, E. J., et al. (2009). Effects of Etanercept and Minocycline injury. Eur. J. Pain 13, 673-681. doi: 10.1016/j.ejpain.2008.08.001
111. Martïnez, J. L. (2008). Antibiotics and antibiotic resistance genes in natural environments. Science 321, 365-367. doi: 10.1126/science.
112. Melzer, N., Meuth, S. G., Torres-Salazar, D., Bittner, S., Zozulya, A. L., Weidenfeller, C., et al. (2008). A beta-lactam antibiotic dampens CNS damage in a mouse model of multiple sclerosis. PLoS ONE 3:e3149. doi: 10.1371/journal.pone.0003149
113. Metz, L. M., Zhang, Y., Yeung, M., Patry, D. G., Bell, R. B., Stoian, C. A., et al. (2004). Minocycline reduces gadolinium lesions in multiple sclerosis. Ann. Neurol. 55, 756. doi: 10.1002/ana.20111
114. Million Passe, C. M., White, C. R., King, M. W., Quirk, P. L., Iovanna, J. L., and Quirk, C. C. (2008). Loss of the protein NUPR1 (p8) delayed ovarian maturation, and testicular development of a sertoli-cell-only syndrome-like phenotype in mice. Biol. Reprod. 10.1095/biolreprod.108.068304
115. Miyamoto, A., Wake, H., Moorhouse, A. J., and Nabekura, J. (2013). Microglia and synapse interactions: fine tuning neural circuits Cell. Neurosci. 7:70. doi: 10.3389/fncel.2013.00070
116. Miyaoka, T. (2008). Clinical potential of minocycline for schizophrenia. CNS Neurol. Disord. Drug Targets 7, 376-381. doi: 10.2174/
117. Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., et al. (2012). Minocycline as adjunctive therapy for patients depression: an open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry 37, 222-226. doi: 10.1016/j.pnpbp.2012. 02.002
118. Monte, S. V., Prescott, W. A., Johnson, K. K., Kuhman, L., and Paladino, J. A. (2008). Safety of ceftriaxone sodium at extremes of age. 523. doi: 10.1517/14740338.7.5.515
119. Mor, F., and Cohen, I. R. (2013). Beta-lactam antibiotics modulate T-cell functions and gene expression via covalent binding to cellular Sci. U.S.A. 110, 2981-2986. doi: 10.1073/pnas.1215722110
120. Morimura, T., Hashiba, M., Kameda, H., Takami, M., Takahama, H., Ohshige, M., et al. (2008). Identification of macrolide antibiotic Antibiot. (Tokyo) 61, 291-296. doi: 10.1038/ja.2008.41
121. Mrowietz, U. (1992). The enigma of cyclosporin A treatment in psoriasis: systemic efficacy versus topical non-responsiveness.
122. Mrowietz, U. (1999). Macrolide immunosuppressants. Eur. J. Dermatol. 9, 346-351.
123. Mutak, S. (2007). Azalides from azithromycin to new azalide derivatives. J. Antibiot. (Tokyo) 60, 85-122. doi: 10.1038/ja.2007.10
124. Nagai, H., Shishido, H., Yoneda, R., Yamaguchi, E., Tamura, A., and Kurashima, A. (1991). Long-term low-dose administration of erythromycin diffuse panbronchiolitis. Respiration 58, 145-149. doi: 10.1159/000195915
125. Nakajima, T., Hishikari, K., Ogawa, M., Watanabe, R., Suzuki, J., Nagashima, A., et al. (2010). Clarithromycin attenuates myocardial Expert Opin. Ther. Targets 14, 881-893. doi: 10.1517/14728222.2010.502890
126. Nakasujja, N., Miyahara, S., Evans, S., Lee, A., Musisi, S., Katabira, E., et al. (2013). Randomized trial ofminocycline in the treatment impairment. Neurology 80, 196-202. doi: 10.1212/WNL.0b013e31827b9121
127. Nizzardo, M., Nardini, M., Ronchi, D., Salani, S., Donadoni, C., Fortunato, F., et al. (2011). Beta-lactam antibiotic offers neuroprotection model by multiple mechanisms. Exp. Neurol. 229, 214-225. doi: 10.1016/j.expneurol.2011.01.017
128. Orsucci, D., Calsolaro, V., Mancuso, M., and Siciliano, G. (2009). Neuroprotective effects of tetracyclines: molecular targets, animal Neurol. Disord. Drug Targets. 8, 222-231. doi: 10.2174/187152709788680689
129. Payne, J. B., and Golub, L. M. (2011). Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory 63, 121-129. doi: 10.1016/j.phrs.2010.10.006
130. Payne, J. B., Golub, L. M., Stoner, J. A., Lee, H. M., Reinhardt, R. A., Sorsa, T., et al. (2011). The effect of subantimicrobial serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J. Am. Dent. Assoc.
131. Periti, P., Mazzei, T., Mini, E., and Novelli, A. (1993). Adverse effects of macrolide antibacterials. Drug Saf. 9, 346-364.
132. Perrins, R. D., Cecere, G., Paterson, I., and Marriott, G. (2008). Synthetic mimetics of actin-bindingmacrolides: rational design of 15, 287-294. doi: 10.1016/j.chembiol.2008.01.010
133. Petersen, P. E., and Ogawa, H. (2012). The global burden of periodontal disease: towards integration with chronic disease prevention 60, 15-39. doi: 10.1111/j.1600-0757.2011.00425.x
134. Powers, R. W. III, Kaeberlein, M., Caldwell, S. D., Kennedy, B. K., and Fields, S. (2006). Extension of chronological life span in yeast signalling. Genes Dev. 20, 174-184. doi: 10.1101/gad.1381406
135. Qiu, Z., and MacRae, T. H. (2007). Developmentally regulated synthesis of p8, a stress-associated transcription cofactor, in diapause franciscana. Cell Stress Chaperones 12, 255-264. doi: 10.1379/CSC-275.1
136. Qrunfleh, A. M., Alazizi, A., and Sari, Y. (2013). Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior Psychopharmacol. 27, 541-549. doi: 10.1177/0269881113482529
137. Rao, P. S., and Sari, Y. (2012). Glutamate transporter 1: target for the treatment of alcohol dependence. Curr. Med. Chem. 10.2174/092986712803530511
138. Rasmussen, B., Unterwald, E. M., and Rawls, S. M. (2011). Glutamate transporter subtype 1 (GLT-1) activator ceftriaxone attenuates hyperactivity and behavioral sensitization in rats. Drug Alcohol Depend. 118, 484-488. doi: 10.1016/j.drugalcdep.2011.03.022
139. Rath, T. (2013). Tacrolimus in transplant rejection. Expert Opin. Pharmacother. 14, 115-122. doi: 10.1517/14656566.2013.751374
140. Rawls, S. M., Baron, D. A., and Kim, J. (2010a). Beta-Lactam antibiotic inhibits development of morphine physical dependence in 164. doi: 10.1097/FBP.0b013e328337be10
141. Rawls, S. M., Zielinski, M., Patel, H., Sacavage, S., Baron, D. A., and Patel, D. (2010b). Beta-lactam antibiotic reduces morphine analgesic GLT-1 transporter activation. Drug Alcohol Depend. 107, 261-263. doi: 10.1016/j.drugalcdep.2009.10.010
142. Rawls, S. M., Cavallo, F., Capasso, A., Ding, Z., and Raffa, R. B. (2008). The beta-lactam antibiotic ceftriaxone inhibits physical dependence withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. Eur. J. Pharmacol. 584, 278
143. Richards, C., Pantanowitz, L., and Dezube, B. J. (2011). Antimicrobial and non-antimicrobial tetracyclines in human cancer trials. 10.1016/j.phrs.2010.10.008
144. Romero, D., Traxler, M. F., López, D., and Kolter, R. (2011). Antibiotics as signal molecules.Chem Rev. 111, 5492-5505. doi: 10.1021/
145. Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., et al. (2005). Beta-lactam antibiotics offer neuroprotection glutamate transporter expression. Nature 433, 73-77. doi: 10.1038/nature03180
146. Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M., and Razak, K. A. (2012). Minocycline treatment reverses ultrasonic vocalization mouse model of Fragile X Syndrome. Brain Res. 1439, 7-14. doi: 10.1016/j.brainres.2011.12.041
147. Roy, S. K., Kendrick, D., Sadowitz, B. D., and Gatto, L. (2011). Jack of all trades: pleiotropy and the application of chemically modified acute respiratory distress syndrome. Pharmacol. Res. 64, 580-589. doi: 10.1016/j.phrs.2011.06.012
148. Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., et al. (1995). Isolation of a protein target complex in mammalian cells. J. Biol. Chem. 270, 815-822. doi: 10.1074/jbc.270.2.815
149. Salo, T., Soini, Y., Oiva, J., Kariylitalo, Nissinen, A., Biancari, F., et al. (2006). Chemically modified tetracyclines (CMT pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition. Int. J. Cardiol. 111, 358-364. doi: 10.1016/
150. Sánchez, A. R., Rogers, R. S. III, and Sheridan, P. J. (2004). Tetracycline and other tetracycline-derivative staining of the teeth and 709-715. doi: 10.1111/j.1365-4632.2004.02108.x
151. Sari, Y., Franklin, K. M., Alazizi, A., Rao, P. S., and Bell, R. L. (2013). Effects of ceftriaxone on the acquisition and maintenance of ethanol and adult female alcohol-preferring (P) rats. Neuroscience 241, 229-238. doi: 10.1016/j.neuroscience.2013.03.016
152. Sari, Y., Sakai, M., Weedman, J. M., Rebec, G. V., and Bell, R. L. (2011). Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption rats. Alcohol Alcohol. 46, 239-234. doi: 10.1093/alcalc/agr023
153. Sari, Y., Smith, K. D., Ali, P. K., and Rebec, G. V. (2009). Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine Neurosci. 29, 9239-9243. doi: 10.1523/JNEUROSCI.1746-09.2009
154. Sbardella, D., Fasciglione, G. F., Gioia, M., Ciaccio, C., Tundo, G. R., Marini, S., et al. (2012). Human matrix metalloproteinases: an involved in several pathological processes. Mol. Aspects Med. 33, 119-208. doi: 10.1016/j.mam.2011.10.015
155. Schultz, M. J. (2004). Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. 54, 21-28. doi: 10.1093/jac/dkh309
156. Schwarz, H., Hickey, C., Zimmerman, C., Mazzoni, P., Moskowitz, C., Rosas, D., et al. (2010). A futility study of minocycline in Huntington 25, 2219-2224. doi: 10.1002/mds.23236
157. Seemungal, T. A. R., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., Sapsford, R. J., and Wedzicha, J. A. (2008). Long decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178, 1139-1147. doi: 10.1164/rccm.
158. Serisier, D. J., Martin, M. L., McGuckin, M. A., Lourie, R., Chen, A. C., Brain, B., et al. (2013). Effect of long-term, low exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309, 1260
159. Sewell, K. L., Breedveld, F., Furrie, E., O'Brien, J., Brinckerhoff, C., Dynesius-Trentham, R., et al. (1996). The effect of minocycline arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Cell. Immunol. 167, 195-204. doi: 10.1006/cimm.1996.0027
160. Shalviri, G., Yousefian, S., and Gholami, K. (2012). Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Clin. Pharm. Ther. 37, 448-451. doi: 10.1111/j.1365-2710.2011.01321.x
161. Shigeri, Y., Seal, R. P., and Shimamoto, K. (2004). Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. 10.1016/j.brainresrev.2004.04.004
162. Siller, S. S., and Broadie, K. (2012). Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. 10.1155/2012/124548
163. Simoens, S., Laekeman, G., and Decramer, M. (2013). Preventing COPD exacerbations with macrolides: a review and budget impact 648. doi: 10.1016/j.rmed.2012.12.019
164. Singh, P. K., Schaefer, A. L., Parsek, M. R., Moninger, T. O., Welsh, M. J., and Greenberg, E. P. (2000). Quorum-sensing signals indicate infected with bacterial biofilms. Nature 407, 762-764. doi: 10.1038/35037627
165. Sirangelo, I., and Irace, G. (2010). Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline Opin. Ther. Targets. 14, 1311-1321. doi: 10.1517/14728222.2010.531012
166. Smith, G. N. Jr., Mickler, E. A., Hasty, K. A., and Brandt, K. D. (1999). Specificity of inhibition of matrix metalloproteinase activity structure of the enzyme. Arthritis Rheum. 42, 1140-1146. doi: 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2
167. Soczynska, J. K., Mansur, R. B., Brietzke, E., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., et al. (2012). Novel therapeutic minocycline as a candidate treatment. Behav. Brain Res. 235, 302-317. doi: 10.1016/j.bbr.2012.07.026
168. Sondheimer, I., and Knackstedt, L. A. (2011). Ceftriaxone prevents the induction of cocaine sensitization and produces enduring attenuation primed reinstatement of cocaine-seeking. Behav. Brain Res. 225, 252-258. doi: 10.1016/j.bbr.2011.07.041
169. Sperandio, V., Torres, A. G., Jarvis, B., Nataro, J. P., and Kaper, J. B. (2003). Bacteria-host communication: the language of hormones. 100, 8951-8956. doi: 10.1073/pnas.1537100100
170. Spinale, F. G., Janicki, J. S., and Zile, M. R. (2013). Membrane-associated matrix proteolysis and heart failure. Circ. Res. 10.1161/CIRCRESAHA.112.266882
171. Steadman, E., Raisch, D. W., Bennett, C. L., Esterly, J. S., Becker, T., Postelnick, M., et al. (2010). Evaluation of a potential clinical and calcium. Antimicrob. Agents Chemother. 54, 1534-1540. doi: 10.1128/AAC.01111-09
172. Stokstad, E. L. R., and Jukes, T. H. (1950). Further observations of the "animal protein factor". Exp. Biol. Med. 72, 523
173. Strachan, D. P. (1989). Hay fever, hygiene, and household size. BMJ 299, 1259-1260. doi: 10.1136/bmj.299.6710.1259
174. Sugimoto, T., Tanikawa, T., Suzuki, K., and Yamasaki, Y. (2012). Synthesis and structure-activity relationship of a novel class of 15 known as '11a-azalides'. Bioorg. Med. Chem. 20, 5787-5801. doi: 10.1016/j.bmc.2012.08.007
175. Suresh Babu, K., Kastelik, J., and Morjaria, J. B. (2013). Role of long-term antibiotics in chronic respiratory diseases. 10.1016/j.rmed.2013.02.009
176. Suzuki, J., Ogawa, M., Hishikari, K., Watanabe, R., Takayama, K., Hirata, Y., et al. (2012). Novel effects of macrolide antibiotics on Cardiovasc. Ther. 30, 301-307. doi: 10.1111/j.1755-5922.2011.00303.x
177. Suzuki, H., Sugimura, Y., Iwama, S., Suzuki, H., Nobuaki, O., Nagasaki, H., et al. (2010). Minocycline prevents osmotic demyelination activation of microglia. J. Am. Soc. Nephrol. 21, 2090-2098. doi: 10.1681/ASN.2010040438
178. Syed, S., Takimoto, C., Hidalgo, M., Rizzo, J., Kuhn, J. G., Hammond, L. A., et al. (2004). A phase I and pharmacokinetic study of Col tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res. 10, 6512-6521. doi: 10.1158/
179. Tamaoki, J., Kadota, J., and Takizawa, H. (2004). Clinical implications of the immunomodulatory effects of macrolides.
180. Tamaoki, J., Takeyama, K., Tagaya, E., and Konno, K. (1995). Effect of clarithromycin on sputum production and its rheological properties tract infections. Antimicrob. Agents Chemother. 39, 1688-1690. doi: 10.1128/AAC.39.8.1688
181. Tarran, R., Sabater, J. R., Clarke, T. C., Tan, C. D., Davies, C. M., Liu, J., et al. (2013). Nonantibiotic macrolides prevent human neutrophil stasis and airway surface liquid volume depletion. Am. J. Physiol. Lung. Cell. Mol. Physiol. 304, L746-L756. doi: 10.1152/ajplung.
182. Tateda, K., Ishii, Y., Kimura, S., Horikawa, M., Miyairi, S., and Yamaguchi, K. (2007). Suppression of Pseudomonas aeruginosa macrolides: a promising strategy or an oriental mystery? J. Infect. Chemother. 13, 357-367. doi: 10.1007/s10156-007-
183. Thomas, P. J., Qu, B. H., and Pedersen, P. L. (1995). Defective protein folding as a basis of human disease. Trends Biochem. Sci. 0004(00)89100-8
184. Thöne-Reineke, C., Neumann, C., Namsolleck, P., Schmerbach, K., Krikov, M., Schefe, J. H., et al. (2008). The beta-lactam antibiotic, improves survival, increases glutamate uptake and induces neurotrophins in stroke. J. Hypertens. 26, 2426-2435. doi: 10.1097/HJH.
185. Tikka, T. M., Fiebich, B. L., Goldsteins, G., Keinanen, R., and Koistinaho, J. (2001). Minocycline, a tetracycline derivative, is neuroprotective inhibiting activation and proliferation of microglia. J. Neurosci. 21, 2580-2588.
186. Tikka, T. M., Vartiainen, N. E., Goldsteins, G., Oja, S. S., Andersen, P. M., Marklund, S. L., et al. (2002). Minocycline prevents neurotoxicity fluid from patients with motor neurone disease. Brain 125, 722-731. doi: 10.1093/brain/awf068
187. Trantham-Davidson, H., LaLumiere, R. T., Reissner, K. J., Kalivas, P. W., and Knackstedt, L. A. (2012). Ceftriaxone normalizes nucleus transmission, glutamate transport, and export following cocaine self-administration and extinction training. J. Neurosci. 10.1523/JNEUROSCI.1976-12.2012
188. Unemo, M., and Nicholas, R. A. (2012). Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhoea. doi: 10.2217/fmb.12.117
189. Vasseur, S., Hoffmeister, A., Garcia, S., Bagnis, C., Dagorn, J. C., and Iovanna, J. L. (2002). p8 is critical for tumour development induced and E1A oncogene. EMBO Rep. 3, 165-170. doi: 10.1093/embo-reports/kvf023
190. Verma, R., Mishra, V., Sasmal, D., and Raghubir, R. (2010). Pharmacological evaluation of glutamate transporter 1 (GLT cerebral ischemia/reperfusion injury. Eur. J. Pharmacol. 638, 65-71. doi: 10.1016/j.ejphar.2010.04.021
191. Vézina, C., Kudelski, A., and Sehgal, S. N. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing the active principle. J Antibiot. (Tokyo) 28, 721-726. doi: 10.7164/antibiotics.28.721
192. Wain, L. V., Soler Artigas, M., and Tobin, M. D. (2012). What can genetics tell us about the cause of fixed airflow obstruction? 10.1111/j.1365-2222.2012.03967.x
193. Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I. G., Cattaneo, E., et al. (2003). Minocycline inhibits caspase cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 10483-10487. doi: 10.1073/pnas.1832501100
194. Watabe, M., Kato, T. A., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., et al. (2013). Minocycline, a microglial inhibitor, reduces economic exchange. Sci. Rep. 3, 1685. doi: 10.1038/srep01685
195. Webster, G., and Del Rosso, J. Q. (2007). Anti-inflammatory activity of tetracyclines. Dermatol. Clin. 25, 133-135. doi: 10.1016/j.det.
196. Wei, J., Pan, X., Pei, Z., Wang, W., Qiu, W., Shi, Z., et al. (2012). The beta-lactam antibiotic, ceftriaxone, provides neuroprotective and anti-inflammation response in a rat model of traumatic brain injury. J. Trauma Acute Care Surg. 73, 654-660. doi: 10.1097/TA.
197. Weinberg, J. M. (2005). The anti-inflammatory effects of tetracyclines. Cutis 75, 6-11.
198. Wiederrecht, G. J., Sabers, C. J., Brunn, G. J., Martin, M. M., Dumont, F. J., and Abraham, R. T. (1995). Mechanism of action of rapamycin: regulation of G1-phase progression in eukaryotic cells. Prog. Cell Cycle Res. 1, 53-71. doi: 10.1007/978-1-4615-1809-9_5
199. Won, S. J., Kim, J. H., Yoo, B. H., Sohn, M., Kauppinen, T. M., Park, M. S., et al. (2012). Prevention of hypoglycemia-induced neuronal Neuroinflammation 9, 225. doi: 10.1186/1742-2094-9-225
200. Wong, R., Beguelin, G. Z., de Lima, M., Giralt, S. A., Hosing, C., Ippoliti, C., et al. (2003). Tacrolimus-associated posterior reversible allogeneic haematopoietic stem cell transplantation. Br. J. Haematol. 122, 128-134. doi: 10.1046/j.1365-2141.2003.04447.x
201. Wright, A. J., Gomes, T., Mamdani, M. M., Horn, J. R., and Juurlink, D. N. (2011). The risk of hypotension following co calcium-channel blockers. CMAJ 183, 303-307. doi: 10.1503/cmaj.100702
202. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., et al. (2002). Blockade of microglial activation is neuroprotective phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.
203. Wu, Q., Marescaux, C., Wolff, V., Jeung, M. Y., Kessler, R., Lauer, V., et al. (2010). Tacrolimus-associated posterior reversible encephalopathy organ transplantation. Eur. Neurol. 64, 169-177. doi: 10.1159/000319032
204. Wullschleger, S., Loewith, R., and Hall, M. N. (2006). TOR signaling in growth and metabolism. Cell 124, 471-484. doi: 10.1016/j.cell.
205. Yim, G., Wang, H. H., and Davies, J. (2006). The truth about antibiotics. Int. J. Med. Microbiol. 296, 163-170. doi: 10.1016/j.ijmm.
206. Yim, G., Wang, H. H., and Davies, J. (2007). Antibiotics as signalling molecules. Philos. Trans. R. Soc. Lond. B Biol. Sci. 10.1098/rstb.2007.2044
207. Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T., and Koisinaho, J. (1998). Tetracyclines inhibit microglial activation and are ischemia. Proc. Natl. Acad. Sci. U.S.A. 95, 15769-15774. doi: 10.1073/pnas.95.26.15769
208. Yrjanheikki, J., Tikka, T., Keinanen, R., Goldsteins, G., Chan, P. H., and Koistinaho, J. (1999). A tetracycline derivative, minocycline, protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U.S.A. 96, 13496-13500. doi: 10.1073/
209. Yuhas, Y., Berent, E., Cohen, R., and Ashkenazi, S. (2009). Role of NF-kappaB activation and peroxisome proliferatoreffect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells. Antimicrob. Agents Chemother. 10.1128/AAC.00961-08
210. Zabad, R. K., Metz, L. M., Todoruk, T. R., Zhang, Y., Mitchell, J. R., Yeung, M., et al. (2007). The clinical response to minocycline in accompanied by beneficial immune changes: a pilot study. Mult. Scler. 13, 517-526.
211. Zhao, L., Xu, J., Yang, Y., Chong, Y., Liu, C., Jiao, Y., et al. (2013a). Inhibitory impacts of chemically modified tetracycline cervical cancer cells. Anticancer Drugs 24, 799-809. doi: 10.1097/CAD.0b013e328362b1be
212. Zhao, Y., Wu, J., Li, J. V., Zhou, N. Y., Tang, H., and Wang, Y. (2013b). Gut microbiota composition modifies faecal metabolic profiles 2987-2999. doi: 10.1021/pr400263n
213. Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y., Ona, V., Li, M., et al. (2002). Minocycline inhibits cytochrome c release and delays lateral sclerosis in mice. Nature 417, 74-78. doi: 10.1038/417074a